Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients

Clinical Pharmacokinetics

Volumn 45, Issue 11, 2006, Pages 1099-1114

  Hennig, Stefanie ^a,b,c   Wainwright, Claire E ^a,c   Bell, Scott C ^a,d   Miller, Hugh ^c   Friberg, Lena E ^a,e   Charles, Bruce G ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b MATER HOSPITAL   (Australia)

^c ROYAL CHILDREN'S HOSPITAL   (Australia)

^d THE PRINCE CHARLES HOSPITAL   (Australia)

^e UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYITRACONAZOLE; ITRACONAZOLE;

ADULT; ARTICLE; BLOOD SAMPLING; BONE MARROW TRANSPLANTATION; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG METABOLISM; FEMALE; FLUOROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MYCOSIS; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTIFUNGAL AGENTS; BIOLOGICAL AVAILABILITY; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; COMPUTER SIMULATION; CYSTIC FIBROSIS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFANT; ITRACONAZOLE; MALE; MODELS, BIOLOGICAL; POPULATION SURVEILLANCE; REPRODUCIBILITY OF RESULTS;

EID: 33750335084     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200645110-00004     Document Type: Article

References (46)

1. Van Cutsem J. The in-vitro antifungal spectrum of itraconazole. Mycoses 1989; 32: 7-13
2. Moss RB. Allergic bronchopulmonary aspergillosis. Clin Rev Allergy Immunol 2002; 23: 87-104
3. Mastella G, Rainisio M, Harms HK, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis: a European epidemiological study. Eur Respir J 2000; 16: 464-71
4. Berner R, Siegfried S, Michalski Y, et al. Central venous catheter infection by aspergillus fumigatus in patients with b-type non-Hodgkin lymphoma. Med Pediatr Oncol 1996; 24: 202-4
5. Bodey GP. Infections in cancer patients. Am J Med 1986; 81: 11-26
6. Jantunen E, Ruutu P, Niskanen L, et al. Incidence and risk factors for invasive fungal infections in allogeneic BMT patients. Bone Marrow Transpl 1997; 19: 801-8
7. Grant S, Clissold S. Itraconazole: a review of its pharmacodynamics and pharmacokinetic properties and therapeutic use in superficial and systemic mycoses. Drugs 1989; 37: 310-44
8. De Beule K, Van Gestel J. Pharmacology of itraconazole. Drugs 2001; 61: 27-37
9. Barone JA, Moskovitz BL, Guarnieri J, et al. Enhanced bioavai-lability of itraconazole in Hydroxypropyl-β-cyclodextrin solution versus capsules in healthy volunteers. Antimicrob Agents Chemother 1998; 42: 1862-5
10. Van de Velde V, Van Peer A, Heykants J, et al. Effect of food on the pharmacokinetics of a new hydroxypropyl β-cyclodextrin formulation of itraconazole. Pharmacotherapy 1996; 16: 424-8
11. Buchkowsky S, Patrtovi N, Ensom M. Clinical pharmacokinetic monitoring of itraconazole is warranted in only a subset of patients. Ther Drug Monit 2005; 27: 322-33
12. Boogaerts MA, Verhoef GE, Zachee P, et al. Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels. Mycoses 1989; 32: 103-8
13. Pandya NA, Atra AA, Riley U, et al. Role of itraconazole in haematology/oncology. Arch Dis Child 2003; 88: 258-60
14. Poirier J-M, Hardy S, Isnard F, et al. Plasma itraconazole concentrations in patients with neutropenia: advantages of a divided daily dosage regimen. Ther Drug Monit 1997; 19: 525-9
15. Foot AB, Veys PA, Gibson BE. Itraconazole oral solution as antifungal prophylaxis in children undergoing stem cell transplantation or intensive chemotherapy for haematological disorders. Bone Marrow Transplant 1999; 24: 1089-93
16. Poirier JM, Cheymol G. Optimisation of itraconazole therapy using target drug concentrations. Clin Pharmacokinet 1998; 35: 461-73
17. Glasmacher A, Hahn C, Leutner C, et al. Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole. Mycoses 1999; 42: 443-51
18. McClean K, Sheehan G. Interactions between itraconazole and digoxin. Clin Infect Dis 1994; 18: 259-60
19. Kemp C, McDowell J, chief editors. Paediatric pharmacopeia. 13th ed. Melbourne: Pharmacy Department, Royal Children's Hospital, 2002
20. Conway SP, Etherington C, Peckham DG, et al. Pharmacokinetics and safety of itraconazole in patients with cystic fibrosis. J Antimicrob Chemother 2004; 53: 841-7
21. Redmann S, Charles BG. A rapid HPLC method with fluorometric detection for determination of plasma itraconazole and hydroxy-itraconazole concentrations in cystic fibrosis children with allergic bronchopulmonary aspergillosis. Biomed Chromatogr 2006 Apr; 20 (4): 343-8
22. Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn 2001; 28: 481-504
23. Wings for NONMEM [online]. Available from URL: http://wfn.sourceforge.net [Accessed 2006 October 12]
24. Karlsson MO, Sheiner LB. The importance of modeling interoc-casion variability in population pharmacokinetic analyses. J Pharmacokinet Biopharm 1993; 21: 735-50
25. Hallynck TH, Soep HH, Thomis JA, et al. Should clearance be normalised to body surface or to lean body mass? Br J Clin Pharmacol 1981; 11: 523-6
26. Boeckmann AJ, Sheiner LB, Beal S. NONMEM users guide-Part V: introductory guide. San Francisco: NONMEM Project Group, University of California at San Francisco, 1994
27. Holford NH. A size standard for pharmacokinetics. Clin Pharmacokinet 1996; 30: 329-32
28. Anderson BJ, McKee AD, Holford NA. Size, myths and the clinical pharmacokinetics of analgesia in paediatric patients. Clin Pharmacokinet 1997; 33: 313-27
29. Yano Y, Beal SL, Sheiner LB. Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn 2001; 28: 171-92
30. Parke J, Charles BG. NONMEM Population pharmacokinetic modelling of orally administered cyclosporine from routine drug monitoring data after heart transplantation. Ther Drug Monit 1998; 20: 284-93
31. Ette EI. Stability and performance of a population pharmacokinetic model. J Clin Pharmacol 1997; 37: 486-95
32. Koks CHW, Huitema ADR, Kroon EDM, et al. Population Pharmacokinetics of Itraconazole in Thai HIV-1-infected persons. Ther Drug Monit 2003; 25: 229-33
33. Willems L, van der Geest R, de Beule K. Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics. J Clin Pharm Ther 2001; 26: 159-69
34. Heykants J, Van Peer A, Van de Velde V, et al. The clinical pharmacokinetics of itraconazole: an overview. Mycoses 1989; 32: 67-87
35. Hardin TC, Graybill JR, Fetchick RJ, et al. Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrob Agents Chemother 1988; 32: 1310-3
36. Reynes J, Bazin C, Ajana F, et al. Pharmacokinetics of itraconazole (oral solution) in two groups of human immunodeficiency virus-infected adults with oral candidiasis. Antimicrob Agents Chemother 1997; 41: 2554-8
37. Sermet-Gaudelus I, Lesne-Hulin A, Lenoir G, et al. Sputum itraconazole concentrations in cystic fibrosis patients. Antimicrob Agents Chemother 2001; 45: 1937-8
38. De Repentigny L, Ratelle J, Lecerc JM, et al. Repeated-dose pharmacokinetics of an oral solution of itraconazole in infants and children. Antimicrob Agents Chemother 1998; 42: 404-8
39. Yoo SD, Kang E, Jun H, et al. Absorption, first-pass metabolism, and disposition of itraconazole in rats. Chem Pharm Bull (Tokyo) 2000; 48: 798-801
40. Rey E, Treluyer JM, Pons G. Drug disposition in cystic fibrosis. Clin Pharmacokinet 1998; 35: 313-29
41. 2-blockers. J Clin Pharmacol 1997; 37: 535-40
42. Gupta A, Katz I, Shear N. Drug interactions with itraconazole, fluconazole and terbinafine and their management. J Am Acad Dermatol 1999; 41: 237-49
43. Kramer M, Marshall S, Denning D, et al. Cyclosporine and itraconazole interaction in heart and lung transplant recipients. Ann Intern Med 1990; 113: 327-9
44. Jaruratanasirikul S, Kleepkaew A. Influence of an acidic beverage (Coca-Cola) on the absorption of itraconazole. Eur J Clin Pharmacol 1997; 52: 235-7
45. Cox KL, Isenberg JN, Ament ME. Gastric acid hypersecretion in cystic fibrosis. J Pediatr Gastroenterol Nutr 1982; 1: 559-65
46. Kintzel PE, Rollins CJ, Yee WJ, et al. Low itraconazole serum concentrations following administration of itraconazole suspension to critically ill allogeneic bone marrow transplant recipients. Ann Pharmacother 1995; 29: 140-3